Sfoglia per Autore
"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy
2026 Peccatori, N; Schwartz, S; Rizzari, C
When Neuromuscular Weakness Is Not Chemotherapy‑Related: Spinal Muscular Atrophy Type II Diagnosed After Acute Lymphoblastic Leukemia Onset in a 1-Year-Old Child: A Case Report and Review of the Literature
2026 Romani, F; Cattaneo, F; Villa, E; Gotti, G; Colombini, A; Dosi, C; Peruzzi, C; Lanfranconi, F; Balduzzi, A; Rizzari, C; Bettini, L
PEDIATRIC PAX5-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IS A HIGH-RISK MOLECULAR SUBGROUP OF B-ALL WITH A POOR MRD-DEPENDENT PROGNOSTIC PROFILE
2026 Peccatori, N; Curto, A; Silvestri, D; Rebellato, S; Antic, Z; Bhatia, S; Bergmann, A; Borkhardt, A; Zimmermann, M; Strehl, S; Nebral, K; Saitta, C; Quadri, M; Palmi, C; Bardini, M; Guardo, D; Lo Nigro, L; Parasole, R; Putti, M; Locatelli, F; Alten, J; Stanulla, M; Valsecchi, M; Buldini, B; Conter, V; Biondi, A; Balduzzi, A; Schrappe, M; Attarbaschi, A; Cario, G; Rizzari, C; Cazzaniga, G; Fazio, G
Successful Treatment of Multirefractory Immune Thrombocytopenia in Rubinstein–Taybi Syndrome With Combined Rituximab and Eltrombopag
2026 Colombo, D; Sala, A; Modola, M; L'Imperio, V; Rambaldi, A; Biondi, A; Balduzzi, A; Rizzari, C; Saettini, F
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis
2025 Di Majo, B; Vendemini, F; Bonanomi, S; Casartelli, P; Napolitano, S; Ottaviano, G; Prunotto, G; Verna, M; Sala, A; Migliorino, G; Petrella, F; Rosso, L; Claut, L; Rafaniello Raviele, P; Rizzari, C; Biondi, A; Balduzzi, A; Lucchini, G
First-Line Postremission Blinatumomab as Successful Toxicity-Sparing Strategy in a Boy with Cystic Fibrosis and Acute Lymphoblastic Leukemia
2025 Peccatori, N; Di Majo, B; Claut, L; Colombini, A; Gotti, G; Leoni, V; Lucchini, G; Sala, A; Spinelli, M; Balduzzi, A; Rizzari, C; Bettini, L
Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and/or high-dose methotrexate-induced acute kidney injury
2025 Peccatori, N; Ardissino, G; Cesaro, S; Danesi, R; Gaspari, S; Meazza, C; Mura, R; Rizzari, C
Case report: Successful treatment of a patient presenting with a very rare association of acute lymphoblastic leukemia and mucopolysaccharidosis type IVA
2025 Arnaboldi, S; Faraguna, M; Colombini, A; Sala, A; Leoni, V; Spinelli, M; Gotti, G; Bettini, L; Crescitelli, V; Commone, A; Gasperini, S; Rizzari, C
Molecularly Targeted Small Molecule Inhibitor Therapy for Pediatric Acute Lymphoblastic Leukemia: A Comprehensive Review of Clinical Trials
2025 Peccatori, N; Brivio, E; Lissat, A; Bautista Sirvent, F; Salzer, E; Biondi, A; Fazio, G; Rizzari, C; Tasian, S; Zwaan, C
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases
2025 Peccatori, N; Coppola, M; Colombini, A; Silvestri, D; Bertorello, N; Kiren, V; Melchionda, F; Mura, R; Onofrillo, D; Gobbi, S; Mattera, R; Vinti, L; Casini, T; Santoro, N; Sperli, D; D'Ippolito, C; Conter, V; Biondi, A; Rizzari, C
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
2024 Conter, V; Valsecchi, M; Cario, G; Zimmermann, M; Attarbaschi, A; Stary, J; Niggli, F; Dalla Pozza, L; Elitzur, S; Silvestri, D; Locatelli, F; Moricke, A; Engstler, G; Smisek, P; Bodmer, N; Barbaric, D; Izraeli, S; Rizzari, C; Boos, J; Buldini, B; Zucchetti, M; Von Stackelberg, A; Matteo, C; Lehrnbecher, T; Lanvers-Kaminsky, C; Cazzaniga, G; Gruhn, B; Biondi, A; Schrappe, M
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia
2024 Bardini, M; Fazio, G; Abascal, L; Meyer, C; Maglia, O; Sala, S; Palamini, S; Rebellato, S; Marschalek, R; Rizzari, C; Biondi, A; Cazzaniga, G
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic target
2024 Taurino, G; Dander, E; Chiu, M; Pozzi, G; Maccari, C; Starace, R; Silvestri, D; Griffini, E; Bianchi, M; Carubbi, C; Andreoli, R; Mirandola, P; Valsecchi, M; Rizzari, C; D'Amico, G; Bussolati, O
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
2023 Rizzari, C; Möricke, A; Valsecchi, M; Conter, V; Zimmermann, M; Silvestri, D; Attarbaschi, A; Niggli, F; Barbaric, D; Stary, J; Elitzur, S; Cario, G; Vinti, L; Boos, J; Zucchetti, M; Lanvers-Kaminsky, C; Von Stackelberg, A; Biondi, A; Schrappe, M
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
2023 Locatelli, F; Zugmaier, G; Rizzari, C; Morris, J; Gruhn, B; Klingebiel, T; Parasole, R; Linderkamp, C; Flotho, C; Petit, A; Micalizzi, C; Zeng, Y; Desai, R; Kormany, W; Eckert, C; Moricke, A; Sartor, M; Hrusak, O; Peters, C; Saha, V; Vinti, L; von Stackelberg, A
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
2023 Moricke, A; Rizzari, C; Alten, J; Attarbaschi, A; Beier, R; Biondi, A; Burkhardt, B; Bodmer, N; Boos, J; Cario, G; Conter, V; Flotho, C; Kulozik, A; Lanvers-Kaminsky, C; Mann, G; Niggli, F; Silvestri, D; Von Stackelberg, A; Stanulla, M; Valsecchi, M; Schrappe, M; Zimmermann, M
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
2022 Cerrano, M; Bonifacio, M; Olivi, M; Curti, A; Malagola, M; Dargenio, M; Scattolin, A; Papayannidis, C; Forghieri, F; Gurrieri, C; Tanasi, I; Zappasodi, P; Starza, R; Fracchiolla, N; Chiusolo, P; Giaccone, L; Del Principe, M; Giglio, F; Defina, M; Favre, C; Rizzari, C; Castella, B; Pizzolo, G; Ferrara, F; Chiaretti, S; Foa, R
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
2022 Pennesi, E; Michels, N; Brivio, E; van der Velden, V; Jiang, Y; Thano, A; Ammerlaan, A; Boer, J; Beverloo, H; Sleight, B; Chen, Y; Vormoor-Burger, B; Rives, S; Bielorai, B; Rossig, C; Petit, A; Rizzari, C; Engstler, G; Stary, J; Bautista Sirvent, F; Chen-Santel, C; Bruno, B; Bertrand, Y; Rialland, F; Plat, G; Reinhardt, D; Vinti, L; Von Stackelberg, A; Locatelli, F; Zwaan, C
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
2022 Siebel, C; Lanvers-Kaminsky, C; Alten, J; Smisek, P; Nath, C; Rizzari, C; Boos, J; Wurthwein, G
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers
2022 Beneduce, G; De Matteo, A; Stellato, P; Testi, A; Bertorello, N; Colombini, A; Putti, M; Rizzari, C; Cesaro, S; Cellini, M; Barisone, E; Petruzziello, F; Menna, G; Parasole, R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile